An observational study in Heart Failure, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Heart Failure by Mayo Clinic — 16 open to participants now, 17 under way, none of them phase 3. Heart Failure · Mayo Clinic.
Among the 69 studies in Heart Failure by Mayo Clinic, this one is the 8th largest by planned enrollment of the 18 observational ones that give a count, is one of 6 that started in 2025, is one of 21 observational ones, reaches primary completion later than 1 of the 16 other live ones, and was the 62nd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →16 of the 69 studies in Heart Failure by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18–80 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 11 · Phase 3 3 · Phase 4 1
First in 1997; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 36 across the 48 interventional studies, 63 across the 18 observational. Of the 48 that completed or were terminated, 15 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
9 of the studies in Heart Failure by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06874556Mayo ClinicA Study of Paramedic HF Management | 2026-12 |
| NCT06762964Mayo ClinicCAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation | 2027-02 |
| NCT06660732Mayo ClinicRilonacept in Subjects With Cardiac Sarcoidosis | 2027-03 |
| NCT05592847Mayo ClinicA Study of the Effect of a Nurse Navigator Program on High Risk Patients | 2027-04 |
| NCT07083011Mayo ClinicA Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure | 2027-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 69 studies in Heart Failure by Mayo Clinic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to see if having community paramedic (CP) visit patients at home to manage their heart failure help them stay out of the hospital and improve their overall health compared to standard care. The investigators want to find out if their approach is better for patients in terms of their quality of life, hospital stays, emergency visits, and cost. The investigators are also looking to see how happy patients and doctors are with this method and if it's a practical and sustainable option for the future.
Patients will be identified by the inpatient cardiology services along with outpatient cardiology and/or primary care offices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
One of the following criteria:
Exclusion Criteria:
Behavioral: CP-HF Management
Community Paramedics will visit patients up to twice daily. Visits will include patient care discussion with Heart Failure APP, IV placement, lab phlebotomy, heart failure education, and IV medication administration. Community Paramedics will administer up to 120 mg IV furosemide twice daily.
Number of Days without Hospitalization
Number of Days without Hospitalization will be measured by the number of days a patient is not admitted to the hospital.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Number of Days in the Hospital
Number of Days in the Hospital will be determined by a patient's length of hospital stay.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Number of Emergency Department (ED) Visits
Number of Emergency Department (ED) Visits will be determined by the number of ED visits per patient
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Number of Hospitalizations
Number of Hospitalizations will be determined by the number of patients that are hospitalized.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-question quality of life questionnaire. The scores can range from 0-105, with a higher score reflecting a worse quality of life
Time frame: Baseline, 31 Days
Number of patients to comply with the guideline-directed medical therapy (GDMT)
Number of patients to comply with the guideline-directed medical therapy (GDMT) will be measured through medical record reviews to determine changes in adherence rates to prescribed HF medications and therapies.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months
Patient Satisfaction
Measured through a structured patient satisfaction survey developed for the CP-HF program. The survey assesses various aspects of patient experience, including communication, responsiveness, medication management, and overall satisfaction. Responses are rated on a 5-point Likert scale (1 = Strongly Disagree, 5 = Strongly Agree), with higher scores indicating greater satisfaction. Additional questions evaluate care coordination, interpreter service utilization, perceived safety, and willingness to recommend the program.
Time frame: up to 1 year
Clinician Satisfaction
Measured through the Clinician \& Stakeholder Satisfaction Survey, which assesses clinician experiences and perceptions of the CP-HF program's effectiveness. The survey includes questions on program structure, implementation, sustainability, and collaboration. Responses are rated on a 5-point Likert scale, with higher scores indicating greater satisfaction.
Time frame: up to 1 year
Stakeholder-Perceived Sustainability
Stakeholder-Perceived Sustainability will be measured through interviews and surveys of key stakeholders to gauge their views on the sustainability and scalability of the CP-HF program.
Time frame: up to 1 year
Cost-effectiveness of Community Paramedic Program
Cost-effectiveness will be determined by comparing the measured cost of the community Paramedic Program against the Standard of Care (SOC)
Time frame: up to 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 18 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.